Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New biomarkers may sharpen cancer diagnosis in bile duct blockages

NCT ID NCT02531607

Diagnosis Sponsor: AdventHealth Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether measuring certain substances in bile and blood can more accurately diagnose cancer in people with bile duct blockages. Researchers will compare these new tests with standard methods in 500 adults undergoing a procedure called ERCP. The goal is to find better ways to tell cancerous from non-cancerous blockages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2014

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for ERCP at the Center for Interventional Endoscopy (CIE)

Ages

19 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Screening Criteria for Potential Participants in the Study 1. Age: ≥18years old 2. Treatment: scheduled for clinical reason to undergo an ERCP at the CIE 3. Suspected of having biliary or pancreatic disease other than cancer (chronic pancreatitis, benign biliary strictures, post-liver transplant strictures, common bile duct stones, sphincter of Oddi dysfunction or suspected of having pancreatic or peri-ampullary malignancy (including pancreatic ductal adenocarcinoma, distal cholangiocarcinoma, ampullary carcinoma, duodenal, carcinoma 4. Clinical or image data suggestive of pancreatic disease or the need for gastrointestinal or pancreatic inspection. 5. Willing and mentally able to provide consent Exclusion Criteria: 1. Age: \<18years old 2. Pregnant women 3. Post-bariatric surgery, hepaticojejunostomy and Bilroth II patients undergoing ERCP. 4. Not scheduled for endoscopic procedures for clinical reasons 5. No clinical or image data suggestive of need for clinical intervention (Endoscopy) 6. Not willing or able to sign informed consent..

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ampullary carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary dyskinesia carcinoma of duodenum carcinoma of the ampulla of vater choledocholithiasis chronic pancreatitis distal biliary tract carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic neoplasms

Contacts and locations

Locations

  • AdventHealth

    Orlando, Florida, 32803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.